Home >> Signaling Pathways >> PI3K/Akt/mTOR Signaling >> mTOR

mTOR

MTOR (mechanistic target of rapamycin) is a serine/threonine kinase that regulates cellular metabolism, growth ad survival. It mediates the cellular response to stress, growth factor and hormone etc. It is involved in cancer, aging and neurodegenerative diseases etc.

Products for  mTOR

  1. Cat.No. Product Name Information
  2. GC17330 (+)-Usniacin (+)-Usniacin is isolated from isolated from lichens, binds at the ATP-binding pocket of mTOR, and inhibits mTORC1/2 activity. (+)-Usniacin inhibits the phosphorylation of mTOR downstream effectors: Akt (Ser473), 4EBP1, S6K, induces autophay, with anti-cancer activity. (+)-Usniacin possesses antimicrobial activity against a number of planktonic gram-positive bacteria, including Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium. (+)-Usniacin  Chemical Structure
  3. GC63524 (32-Carbonyl)-RMC-5552 (32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. (32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2 substrate (p-P70S6K-(T389), p-4E-BP1-(T37/36), AND p-AKT1/2/3-(S473)) phosphorylation with pIC50s of > 9, >9 and between 8 and 9, respectively (patent WO2019212990A1, example 2). (32-Carbonyl)-RMC-5552  Chemical Structure
  4. GC32767 3BDO A butyrolactone derivative and autophagy inhibitor 3BDO  Chemical Structure
  5. GC35395 Arnicolide D Arnicolide D is a sesquiterpene lactone isolated from Centipeda minima. Arnicolide D modulates the cell cycle, activates the caspase signaling pathway and inhibits the PI3K/AKT/mTOR and STAT3 signaling pathways. Arnicolide D inhibits Nasopharyngeal carcinoma (NPC) cell viability in a concentration- and time-dependent manner. Arnicolide D  Chemical Structure
  6. GC13029 AZD2014 AZD2014 (AZD2014) is an ATP competitive mTOR inhibitor with an IC50 of 2.81 nM. AZD2014 inhibits both mTORC1 and mTORC2 complexes. AZD2014  Chemical Structure
  7. GC16380 AZD8055 MTOR inhibitor AZD8055  Chemical Structure
  8. GC13271 BEZ235 Tosylate BEZ235 Tosylate  Chemical Structure
  9. GC35509 BGT226 BGT226 (NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ)/mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells. BGT226  Chemical Structure
  10. GC30229 Cbz-B3A Cbz-B3A is a potent and selective inhibitor of mTORC1 signaling that appear to bind to ubiquilins 1, 2, and 4, and Cbz-B3A inhibits the phosphorylation of eIF4E-binding protein 1 (4EBP1). Cbz-B3A  Chemical Structure
  11. GC16654 CC-115 mTOR/DNA-PK inhibitor CC-115  Chemical Structure
  12. GC34121 CC-115 hydrochloride CC-115 hydrochloride is a potent and dual DNA-PK and mTOR kinase inhibitor with IC50s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling. CC-115 hydrochloride  Chemical Structure
  13. GC13648 CC-223 CC-223 (CC-223) is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, with an IC50 value for mTOR kinase of 16 nM. CC-223 inhibits both mTORC1 and mTORC2. CC-223  Chemical Structure
  14. GC65944 CC214-2 CC214-2 is a potent and dual inhibitor of mTORC1/mTORC2. Mycobacterium tuberculosis modulates mammalian target of rapamycin (mTOR) signaling to impede autophagy. CC214-2 has the potential to shorten the duration of TB. CC214-2  Chemical Structure
  15. GC38419 Cyclovirobuxine D An alkaloid with diverse biological activities Cyclovirobuxine D  Chemical Structure
  16. GC19114 CZ415 CZ415 is a potent and highly selective mTOR inhibitor with a pIC50 of 8.07. CZ415  Chemical Structure
  17. GC18583 D-α-Hydroxyglutaric Acid Over-produced in the human neurometabolic disease D-2-HGA D-α-Hydroxyglutaric Acid  Chemical Structure
  18. GN10583 Dihydromyricetin Dihydromyricetin  Chemical Structure
  19. GC62495 DS-7423 DS-7423 is a dual PI3K and mTOR inhibitor, with IC50 values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity. DS-7423  Chemical Structure
  20. GC43585 eCF309 eCF309 is an ATP-competitive inhibitor of mTOR (IC50 = 15 nM in vitro and in cells) with >65-fold selectivity over other kinases, including PI3Ks. eCF309  Chemical Structure
  21. GC10196 ETP-46464 ATR inhibitor,potent and selective ETP-46464  Chemical Structure
  22. GC13601 Everolimus (RAD001) A rapamycin derivative Everolimus (RAD001)  Chemical Structure
  23. GC33355 FT-1518 FT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity. FT-1518  Chemical Structure
  24. GC10228 GDC-0084 PI3K and mTOR inhibitor, brain-permeable GDC-0084  Chemical Structure
  25. GC12021 GDC-0349 MTOR inhibitor GDC-0349  Chemical Structure
  26. GC11177 GDC-0980 (RG7422) GDC-0980 (RG7422) (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I PI3 kinase and mTOR kinase (TORC1/2) inhibitor with IC50s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ, and with aKiof 17 nM for mTOR. GDC-0980 (RG7422)  Chemical Structure
  27. GC10900 GDC-mTOR inhibitor GDC-mTOR inhibitor  Chemical Structure
  28. GC17338 GNE-317 potent, brain-penetrant PI3K inhibitor GNE-317  Chemical Structure
  29. GC10340 GNE-477 dual PI3K/mTOR inhibitor GNE-477  Chemical Structure
  30. GC15423 GNE-493 Pan-PI3K/mTOR inhibitor GNE-493  Chemical Structure
  31. GC11018 GSK1059615 PI3K and mTOR inhibitor,potent and reversible GSK1059615  Chemical Structure
  32. GC15072 GSK2126458 GSK2126458 (GSK2126458) is an orally active and highly selective inhibitor of PI3K with Kis of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively. GSK2126458 has anti-cancer activity. GSK2126458  Chemical Structure
  33. GA10282 H-Leu-OH H-Leu-OH  Chemical Structure
  34. GC65460 HDACs/mTOR Inhibitor 1 HDACs/mTOR Inhibitor 1 is a dual Histone Deacetylases (HDACs) and mammalian target of Rapamycin (mTOR) target inhibitor for treating hematologic malignancies, with IC50s of 0.19 nM, 1.8 nM, 1.2 nM and >500 nM for HDAC1, HDAC6, mTOR and PI3Kα, respectively. HDACs/mTOR Inhibitor 1 stimulates cell cycle arrest in G0/G1 phase and induce tumor cell apoptosis with low toxicity in vivo. HDACs/mTOR Inhibitor 1  Chemical Structure
  35. GC38088 Hederacolchiside A1 Hederacolchiside A1  Chemical Structure
  36. GC62572 hSMG-1 inhibitor 11e hSMG-1 inhibitor 11e is a potent and selective hSMG-1 kinase inhibitor with an IC50 of 900-fold selectivity over mTOR (IC50 of 45 nM), PI3Kα/γ (IC50s of 61 nM and 92 nM) and CDK1/CDK2 (IC50s of 32 μM and 7.1 μM). hSMG-1 inhibitor 11e  Chemical Structure
  37. GC61925 hSMG-1 inhibitor 11j hSMG-1 inhibitor 11j, a pyrimidine derivative, is a potent and selective inhibitor of hSMG-1, with an IC50 of 0.11 nM. hSMG-1 inhibitor 11j exhibits >455-fold selectivity for hSMG-1 over mTOR (IC50=50 nM), PI3Kα/γ (IC50=92/60 nM) and CDK1/CDK2 (IC50=32/7.1 μM). hSMG-1 inhibitor 11j can be used for the research of cancer. hSMG-1 inhibitor 11j  Chemical Structure
  38. GC10969 INK 128(MLN0128) INK 128 (MLN0128) (INK-128; MLN0128; TAK-228) is an orally available, ATP-dependent mTOR1/2 inhibitor with an IC50 of 1 nM for mTOR kinase. INK 128(MLN0128)  Chemical Structure
  39. GC34909 JR-AB2-011 A selective mTORC2 inhibitor JR-AB2-011  Chemical Structure
  40. GC14346 KU-0060648 Dual DNA-PK/PI3-K inhibitor, ATP-competitive KU-0060648  Chemical Structure
  41. GC15167 KU-0063794 MTORC1 and mTORC2 inhibitor KU-0063794  Chemical Structure
  42. GC68037 L-Leucine-1-13C,15N L-Leucine-1-13C,15N  Chemical Structure
  43. GC68219 L-Leucine-13C L-Leucine-13C  Chemical Structure
  44. GC63833 L-Leucine-15N L-Leucine-15N  Chemical Structure
  45. GC66357 L-Leucine-d2 L-Leucine-d2 is the deuterium labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. L-Leucine-d2  Chemical Structure
  46. GC64188 L-Leucine-d3 L-Leucine-d3 is the deuterium labeled L-Leucine. L-Leucine-d3  Chemical Structure
  47. GC12045 LY 303511 An inhibitor of cell proliferation LY 303511  Chemical Structure
  48. GC14371 LY3023414 LY3023414 (LY3023414) potently and selectively inhibits class I PI3K isoforms, DNA-PK, and mTORC1/2 with IC50s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. LY3023414 potently inhibits mTORC1/2 at low nanomolar concentrations. LY3023414  Chemical Structure
  49. GC64402 MHY-1685 MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, provides opportunities to improve hCSC-based myocardial regeneration. MHY-1685  Chemical Structure
  50. GC13790 MHY1485

    MHY1485 is a potent activator of mTOR, which inhibits autophagy and the fusion between autophagosomes and lysosomes.

    MHY1485  Chemical Structure
  51. GC65143 MKC-1 MKC-1 (Ro-31-7453) is an orally active and potent cell cycle inhibitor with broad antitumor activity. MKC-1 inhibits the Akt/mTOR pathway. MKC-1 arrests cellular mitosis and induces cell apoptosis by binding to a number of different cellular proteins including tubulin and members of the importin β family. MKC-1  Chemical Structure
  52. GC60258 MT 63-78 MT 63-78 is a specific and potent direct AMPK activator with an EC50 of 25 μM. MT 63–78 also induces cell mitotic arrest and apoptosis. MT 63-78 blocks prostate cancer growth by inhibiting the lipogenesis and mTORC1 pathways. MT 63-78 has antitumor effects. MT 63-78  Chemical Structure
  53. GC64304 MTI-31 MTI-31 is a potent, orally active and highly selective inhibitor of mTORC1 and mTORC2. MTI-31  Chemical Structure
  54. GC65115 mTOR inhibitor-1 mTOR inhibitor-1 is a novel mTOR pathway inhibitor which can suppress cells proliferation and inducing autophagy. mTOR inhibitor-1  Chemical Structure
  55. GC62339 mTOR inhibitor-8 mTOR inhibitor-8 is an mTOR inhibitor and autophagy inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells. mTOR inhibitor-8  Chemical Structure
  56. GC18089 Nordihydroguaiaretic acid A non-selective LO inhibitor Nordihydroguaiaretic acid  Chemical Structure
  57. GC33014 NSC781406 A dual inhibitor of PI3K and mTOR NSC781406  Chemical Structure
  58. GC63121 NV-5138 NV-5138, a leucine analog, is the first selective and orally active brain mTORC1 activator, binding to Sestrin2. NV-5138  Chemical Structure
  59. GC63122 NV-5138 hydrochloride NV-5138 hydrochloride, a leucine analog, is the first selective and orally active brain mTORC1 activator, binding to Sestrin2. NV-5138 hydrochloride  Chemical Structure
  60. GC16145 NVP-BGT226 BGT226 (NVP-NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ) /mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells. NVP-BGT226  Chemical Structure
  61. GC14071 OSI-027 MTORC1/ mTORC2 inhibitor OSI-027  Chemical Structure
  62. GC15740 OXA-01 mTORC1 and mTORC2 inhibitor OXA-01  Chemical Structure
  63. GC12773 Palomid 529

    PI3K/Akt/mTOR inhibitor

    Palomid 529  Chemical Structure
  64. GC16417 PF-04691502 PI3K/mTOR (FRAP) inhibitor PF-04691502  Chemical Structure
  65. GC19283 PF-04979064 PF-04979064 is a potent and selective PI3K/mTOR dual kinase inhibitor with Kis of 0.13 nM and 1.42 nM for PI3Kα and mTOR, respectively. PF-04979064  Chemical Structure
  66. GC15653 PF-05212384 (PKI-587) PF-05212384 (PKI-587) (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC50s of 0.4 nM, 5.4 nM and 1.6 nM, respectively. PF-05212384 (PKI-587) is equally effective in both complexes of mTOR, mTORC1 and mTORC2. PF-05212384 (PKI-587)  Chemical Structure
  67. GC11165 PI-103 Class I PI3K, mTOR and DNA-PK inhibitor PI-103  Chemical Structure
  68. GC16379 PI-103 Hydrochloride A potent, cell-permeable PI3K inhibitor PI-103 Hydrochloride  Chemical Structure
  69. GC36909 PI3Kα/mTOR-IN-1 PI3Kα/mTOR-IN-1 is a potent PI3Kα/mTOR dual inhibitor, with an IC50 of 7 nM for PI3Kα in a cell assay, and Kis of 10.6 nM and 12.5 nM for mTOR and PI3Kα in a cell free assay , respectively. PI3Kα/mTOR-IN-1  Chemical Structure
  70. GC62140 PKI-179 PKI-179 is a potent and orally active dual PI3K/mTOR inhibitor, with IC50s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for PI3K-α, PI3K-β, PI3K-γ, PI3K-δ and mTOR, respectively. PKI-179 also exhibits activity over E545K and H1047R, with IC50s of 14 nM and 11 nM, respectively. PKI-179 shows anti-tumor activity in vivo. PKI-179  Chemical Structure
  71. GC17104 PKI-402

    PI3K inhibitor,selective, reversible and ATP-competitive

    PKI-402  Chemical Structure
  72. GN10709 Polyphyllin A Polyphyllin A  Chemical Structure
  73. GC33115 Pomiferin (NSC 5113) Pomiferin (NSC 5113) (NSC 5113) acts as an potential inhibitor of HDAC, with an IC50 of 1.05 μM, and also potently inhibits mTOR (IC50, 6.2 μM). Pomiferin (NSC 5113)  Chemical Structure
  74. GC11003 PP121 Dual inhibitor of tyrosine and phosphoinositide kinases PP121  Chemical Structure
  75. GC15904 PP242 PP242 (PP 242) is a selective and ATP-competitive mTOR inhibitor with an IC50 of 8 nM. PP242 inhibits both mTORC1 and mTORC2 with IC50s of 30 nM and 58 nM, respectively. PP242  Chemical Structure
  76. GC33385 PQR-530 A dual inhibitor of PI3Kα and mTOR PQR-530  Chemical Structure
  77. GC19300 PQR309 PQR309 (PQR309) is a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor with IC50s of 33 nM, 451 nM, 661 nM, 708 nM and 89 nM for PI3Kα, PI3Kδ, PI3Kβ, PI3Kγ and mTOR, respectively. PQR309 is an mTORC1 and mTORC2 inhibitor. PQR309  Chemical Structure
  78. GC32891 PQR620 PQR620 is an orally bioavailable and selective brain penetrant inhibitor of mTORC1/2. PQR620  Chemical Structure
  79. GC18032 QL-IX-55 QL-IX-55  Chemical Structure
  80. GC11607 Rapalink-1 third-generation mTOR inhibitor Rapalink-1  Chemical Structure
  81. GC15031 Rapamycin (Sirolimus)

    An allosteric inhibitor of mTORC1

    Rapamycin (Sirolimus)  Chemical Structure
  82. GC48027 Rapamycin-d3 An internal standard for the quantification of rapamycin Rapamycin-d3  Chemical Structure
  83. GC39292 Rheb inhibitor NR1 Rheb inhibitor NR1 is a Rheb inhibitor with an IC50 of 2.1??M in the Rheb-IVK assay. Rheb inhibitor NR1  Chemical Structure
  84. GC13071 Ridaforolimus (Deforolimus, MK-8669) Ridaforolimus (Deforolimus, MK-8669) (MK-8669) is a potent and selective mTOR inhibitor; inhibits ribosomal protein S6 phosphorylation with an IC50 of 0.2 nM in HT-1080 cells. Ridaforolimus (Deforolimus, MK-8669)  Chemical Structure
  85. GC62649 RMC-5552 RMC-5552 is a potent and selective inhibitor of mTORC1. RMC-5552 inhibits phosphorylation of mTORC1 pS6K and p4EBP1 with IC50s of 0.14 nM and 0.48 nM, respectively. RMC-5552 has anti-cancer activity. RMC-5552  Chemical Structure
  86. GC63894 RMC-6272 RMC-6272 (RM-006) is a bi-steric mTORC1-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors. RMC-6272  Chemical Structure
  87. GC38609 Rotundic acid Rotundic acid, a triterpenoid obtained from I. Rotundic acid  Chemical Structure
  88. GC64278 RP-3500 RP-3500 (ATR inhibitor 4) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC50 of 1.00 nM in biochemical assays. RP-3500 shows 30-fold selectivity for ATR over mTOR (IC50=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. RP-3500 has potent antitumor activity. RP-3500  Chemical Structure
  89. GN10127 Salidroside Salidroside is a glycoside with multiple biological activities and has pharmacological effects such as anti-cancer, antioxidant, anti-aging, anti-diabetic, anti-diabetic, anti-hypertensive, anti-inflammatory, and immune regulation. Salidroside  Chemical Structure
  90. GC12573 Temsirolimus

    A MTOR inhibitor

    Temsirolimus  Chemical Structure
  91. GC61336 TMBIM6 antagonist-1 TMBIM6 antagonist-1, a potential TMBIM6 antagonist, prevents TMBIM6 binding to mTORC2, decreases mTORC2 activity, and also regulates TMBIM6-leaky Ca2+. TMBIM6 antagonist-1  Chemical Structure
  92. GC10131 Torin 1

    MTOR inhibitor,potent and selective

    Torin 1  Chemical Structure
  93. GC13858 Torin 2 MTOR inhibitor,highly potent and selective Torin 2  Chemical Structure
  94. GC37922 Voxtalisib A dual inhibitor of PI3K and mTORC Voxtalisib  Chemical Structure
  95. GC17771 VS-5584 (SB2343) A selective PI3K/mTOR kinase inhibitor VS-5584 (SB2343)  Chemical Structure
  96. GC10583 WAY-600 MTOR inhibitor WAY-600  Chemical Structure
  97. GC14675 WYE-125132 (WYE-132) WYE-125132 (WYE-132) (WYE-125132) is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor (IC50: 0.19±0.07 nM; >5,000-fold selective versus PI3Ks). WYE-125132 (WYE-132) (WYE-125132) inhibits mTORC1 and mTORC2. WYE-125132 (WYE-132)  Chemical Structure
  98. GC13321 WYE-687 MTOR inhibitor,ATP-competitive and selective WYE-687  Chemical Structure
  99. GC38473 WYE-687 dihydrochloride WYE-687 dihydrochloride is an ATP-competitive mTOR inhibitor with an IC50 of 7 nM. WYE-687 dihydrochloride concurrently inhibits activation of mTORC1 and mTORC2. WYE-687 also inhibits PI3Kα and PI3Kγ with IC50s of 81 nM and 3.11 μM, respectively. WYE-687 dihydrochloride  Chemical Structure
  100. GC16481 XL388 An mTOR inhibitor XL388  Chemical Structure

99 Item(s)

per page

Set Descending Direction